Evidence map›Paper›PMID 41025386›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2026

Longitudinal Blood-Biomarker-Based Assessment of Brain Injury in Patients Undergoing Deep Brain Stimulation and Magnetic Resonance-Guided Focused Ultrasound.

Justina Dargvainiene, Ann-Kristin Helmers, Juliana Naumann, Carl Alexander Gless, Bettina Möller, Julius Welzel, Frank Leypoldt, Johannes Hensler, Ina Tesseur, Klaus-Peter Wandinger and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Justina DargvainieneInstitute of Clinical Chemistry, University Medical Center Schleswig-Holstein, Kiel, Germany.
Ann-Kristin HelmersDepartment of Neurosurgery, University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel, Germany.
Juliana NaumannDepartment of Neurology, University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel, Germany.
Carl Alexander GlessDepartment of Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel, Germany.
Bettina MöllerDepartment of Neurology, University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel, Germany.
Julius WelzelDepartment of Neurology, University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel, Germany.
Frank LeypoldtInstitute of Clinical Chemistry, University Medical Center Schleswig-Holstein, Kiel, Germany.
Johannes HenslerDepartment of Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel, Germany.
Ina TesseurUCB, Braine-l'Alleud, Belgium.
Klaus-Peter WandingerInstitute of Clinical Chemistry, University Medical Center Schleswig-Holstein, Kiel, Germany.
Günther DeuschlDepartment of Neurology, University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel, Germany.ORCID https://orcid.org/0000-0002-4176-9196
Daniela BergDepartment of Neurology, University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel, Germany.
Steffen PaschenDepartment of Neurology, University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel, Germany.ORCID https://orcid.org/0000-0002-9306-8332

Funding

UCB Pharma
6 · The paper itself

Abstract

backgroundDeep brain stimulation (DBS) and magnetic resonance-guided focused ultrasound (MRgFUS) are associated with neuroaxonal damage and astroglial activation; yet their extent and timing remain unclear despite clinical relevance for monitoring and outcome assessment.

objectiveThis study assessed neuroaxonal damage and astroglial activation after DBS (n = 21) and MRgFUS (n = 19) reflected by serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP).

methodsSamples were collected at baseline, 24 h, 7 days, and 3/6/9 months posttreatment. Biomarker levels were measured using a single-molecule array (Simoa).

resultssNfL peaked at day 7 and sGFAP at 24 h post-intervention in both groups. sNfL normalized at 6 months in DBS and 3 months in MRgFUS. sGFAP normalized within 7 days in both groups. Biomarker elevations were higher in DBS patients.

conclusionsDBS and MRgFUS cause transient neuroaxonal injury and astroglial activation, with greater extent in DBS. Biomarker monitoring suggests final clinical evaluation should be performed 6 months after treatment at the earliest. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Indexed as

Brain InjuriesDeep Brain StimulationGlial Fibrillary Acidic ProteinNeurofilament ProteinsParkinson DiseaseAdultAgedBiomarkersFemaleHumansLongitudinal StudiesMagnetic Resonance ImagingMaleMiddle AgedBiomarkersGlial Fibrillary Acidic Proteinneurofilament protein LNeurofilament Proteinsdeep brain stimulationglial fibrillary acidic protein (GFAP)magnetic resonance–guided focused ultrasound (MRgFUS)neurofilament light chain (NfL)

Identifiers

PMID41025386
PMCPMC12882050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.